
- Volume 0 0
Trial Weighs Risks/Benefits of Raloxifene
New research shows that the osteoporosisdrug raloxifene (Evista), nowused to help prevent breast cancer,does not increase a woman's risk ofcoronary heart disease. For womenalready at a higher risk for coronaryheart disease or for women whoalready have it, however, raloxifeneincreased the risk of fatal stroke andblood clots, according to new clinicaltrial data. The trial, Raloxifene Use forThe Heart (RUTH), included data frommore than 10,000 postmenopausalwomen with coronary heart disease orassociated risk factors. Participantsrandomly received either 60 mg/day ofraloxifene or placebo and were followedfor about 5 years. Raloxifene hadno significant effect on the women'scoronary heart disease risk, but thewomen in this group had a 55% higherrisk for fatal stroke and a 44% increasedrisk for blood clots. Whetherthe risk of stroke and blood clot outweighsthe drug's benefits in preventingbreast cancer remains an individualdecision, according to the studyauthors. "In our study, there werealmost an equal number of risks asthere were benefits. It's a very individualdecision," advises investigator LoriMosca, MD, MPH, PhD. Study resultswere published in the July 13, 2006, issueof The New England Journal of Medicine.
Ms. Farley is a freelance medicalwriter based in Wakefield, RI.
Articles in this issue
about 19 years ago
Pharmacy Technology Productsabout 19 years ago
Tobacco Useabout 19 years ago
Rx Product Newsabout 19 years ago
OTC Product Newsabout 19 years ago
can you READ theseRxs?about 19 years ago
Generic Times Product Newsabout 19 years ago
compoundingHOTLINEabout 19 years ago
Compounding for Pediatric Patientsabout 19 years ago
Vaccinations: Current Research and Perceptionsabout 19 years ago
Police and Drug TestingNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.